Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma

British Journal of Haematology

Volumn 148, Issue 2, 2010, Pages 256-267

  Bates, Susan E ^a   Zhan, Zhirong ^a   Steadman, Kenneth ^a   Obrzut, Tomasz ^a   Luchenko, Victoria ^a   Frye, Robin ^a   Robey, Robert W ^a   Turner, Maria ^a   Gardner, Erin R ^b   Figg, William D ^c   Steinberg, Seth M ^c   Ling, Alex ^d   Fojo, Tito ^a   To, Kin Wah ^a   Piekarz, Richard L ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Fetal haemoglobin; Histone deacetylase inhibitor; P glycoprotein; Romidepsin; T cell lymphoma

Indexed keywords

HEMOGLOBIN F; HISTONE H3; MULTIDRUG RESISTANCE PROTEIN 1; ROMIDEPSIN;

ACETYLATION; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DRUG CLEARANCE; DRUG WITHDRAWAL; FETUS BLOOD; GENE EXPRESSION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; LABORATORY TEST; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL T CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY;

ACETYLATION; ANTIBIOTICS, ANTINEOPLASTIC; BIOPSY; DEPSIPEPTIDES; FETAL HEMOGLOBIN; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; IMMUNOBLOTTING; LEUKOCYTES, MONONUCLEAR; LYMPHOMA, T-CELL; LYMPHOMA, T-CELL, PERIPHERAL; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN NEOPLASMS;

EID: 72649091422     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07954.x     Document Type: Article

References (52)

1. Archer, S.Y., Meng, S., Shei, A. Hodin, R.A. (1998) p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 95, 6791 6796.
2. Atmaca, A., Al-Batran, S.E., Maurer, A., Neumann, A., Heinzel, T., Hentsch, B., Schwarz, S.E., Hövelmann, S., Gottlicher, M., Knuth, A. Jager, E. (2007) Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. British Journal of Cancer, 97, 177 182.
3. de Bono, J.S., Kristeleit, R., Tolcher, A., Fong, P., Pacey, S., Karavasilis, V., Mita, M., Shaw, H., Workman, P., Kaye, S., Rowinsky, E.K., Aherne, W., Atadja, P., Scott, J.W. Patnaik, A. (2008) Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clinical Cancer Research, 14, 6663 6673.
4. Byrd, J.C., Marcucci, G., Parthun, M.R., Xiao, J.J., Klisovic, R.B., Moran, M., Lin, T.S., Liu, S., Sklenar, A.R., Davis, M.E., Lucas, D.M., Fischer, B., Shank, R., Tejasw, S.L., Binkley, P., Wright, J., Chan, K.K. Grever, M.R. (2005) A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood, 105, 959 967.
5. Cao, H. Stamatoyannopoulos, G. (2006) Histone deacetylase inhibitor FK228 is a potent inducer of human fetal hemoglobin. American Journal of Hematology, 81, 981 983.
6. Chen, C.J., Chin, J.E., Ueda, K., Clark, D.P., Pastan, I., Gottesman, M.M. Roninson, I.B. (1986) Internal duplication and homology with bacterial transport proteins in mdr-1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell, 47, 371 380.
7. Chen, J., Zhang, M., Ju, W. Waldmann, T.A. (2009) Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25. Blood, 113, 1287 1293.
8. Coleman, E. Inusa, B. (2007) Sickle cell anemia: targeting the role of fetal hemoglobin in therapy. Clinical Pediatrics (Philadelphia), 46, 386 391.
9. Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J.H., Reilly, J.F., Ricker, J.L., Richon, V.M. Frankel, S.R. (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood, 109, 31 39. (Pubitemid 46053039)
10. Ellis, L., Pann, Y., Smyth, G.K., George, D.J., McCormack, C., Williams-Truax, R., Mita, M., Beck, J., Burris, H., Ryan, G., Atadja, P., Butterfoss, D., Dugan, M., Culver, K., Johnstone, R.W. Prince, H.M. (2008) Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clinical Cancer Research, 14, 4500 4510.
11. Furumai, R., Matsuyama, A., Kobashi, N., Lee, K.H., Nishiyama, M., Nakajima, H., Tanaka, A., Komatsu, Y., Noshino, N., Yoshida, M. Horinouchi, S. (2002) FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Research, 62, 4916 4921.
12. Garcia-Manero, G., Yang, H., Bueso-Ramos, C., Ferrajoli, A., Cortes, J., Wierda, W.G., Faderl, S., Koller, C., Morris, G., Rosner, G., Loboda, A., Fantin, V.R., Randolph, S.S., Hardwick, J.S., Reilly, J.F., Chen, C., Ricker, J.L., Secrist, J.P., Richon, V.M., Frankel, S.R. Kantarjian, H.M. (2008) Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood, 111, 1060 1066.
13. Gimsing, P., Hansen, M., Knudsen, L.M., Knoblauch, P., Christensen, I.J., Ooi, C.E. Buhl-Jennsen, P. (2008) A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. European Journal of Haematology, 81, 170 176.
14. Gojo, I., Jiemjit, A., Trepel, J.B., Sparreboom, A., Figg, W.D., Rollins, S., Tidwell, M.L., Greer, L., Chung, E.L., Lee, M.J., Gore, S.D., Sausville, E.A., Zwiebel, J. Karp, J.E. (2007) Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood, 109, 2781 2790.
15. Herzog, C.E., Trepel, J.B., Mickley, L.A., Bates, S.E. Fojo, A.T. (1992) Various methods of analysis of mdr-1/P-glycoprotein in human colon cancer cell lines. Journal of the National Cancer Institute, 84, 711 716.
16. Imai, T., Adachi, S., Nishijo, K., Ohgushi, M., Okada, M., Yasumi, T., Watanabe, K., Nishikomori, R., Nakayama, T., Yonehara, S., Toguchida, J. Nakahata, T. (2003) FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells. Oncogene, 22, 9231 9242.
17. Insinga, A., Monestiroli, S., Ronzoni, S., Gelmetti, V., Marchesi, F., Viale, A., Altucci, L., Vervi, C., Minucci, S. Pelicci, P.G. (2005) Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nature Medicine, 11, 71 76.
18. Jin, S. Scotto, K.W. (1998) Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Molecular and Cellular Biology, 18, 4377 4384.
19. Kelly, W.K., O'Connor, O.A., Krug, L.M., Chiao, J.H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J.P., Schwartz, L., Richardson, S., Chu, E., Olegac, S., Marks, P.A., Scher, H. Richon, V.M. (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. Journal of Clinical Oncology, 23, 3923 3931.
20. Kitazono, M., Robey, R., Zhan, Z., Sarlis, N.J., Skarulis, M.C., Aikou, T., Bates, S. Fojo, T. (2001) Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. Journal of Clinical Endocrinology and Metabolism, 86, 3430 3435.
21. Klisovic, D.D., Katz, S.E., Effron, D., Klisovic, M.I., Wickham, J., Parthun, M.R., Guimond, M. Marcucci, G. (2003) Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines. Investigative Ophthalmology and Visual Science, 44, 2390 2398.
22. Kummar, S., Gutierrez, M., Gardner, E.R., Donovan, E., Hwang, K., Chung, E.J., Lee, M.J., Maynard, K., Kalnitskiy, M., Chen, A., Melillo, G., Ryan, Q.C., Conley, B., Figg, W.D., Trepel, J.B., Zwiebel, J., Doroshow, J.H. Murgo, A. (2007) Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clinical Cancer Research, 13, 5411 5417.
23. Lea, M.A., Ibeh, C., Shah, N. Moyer, M.P. (2007) Induction of differentiation of colon cancer cells by combined inhibition of kinases and histone deacetylase. Anticancer Research, 27, 741 748.
24. Lee, J.S., Paull, K., Alvarez, M., Hose, C., Monks, A., Grever, M., Fojo, A.T. Bates, S.E. (1994) Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute Drug Screen. Molecular Pharmacology, 46, 627 638.
25. Lin, H.Y., Chan, C.S., Lin, S.P., Weng, J.R. Chen, C.S. (2006) Targeting histone deacetylase in cancer therapy. Medicinal Research Reviews, 26, 397 413.
26. Marks, P.A., Richon, V.M. Rifkind, R.A. (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. Journal of the National Cancer Institute, 92, 1210 1216.
27. Mickley, L.A., Bates, S.E., Richert, N.D., Currier, S., Tanaka, S., Foss, F., Rosen, N. Fojo, A.T. (1989) Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents. Journal of Biological Chemistry, 264, 18031 18040.
28. Munster, P.N., Troso-Sandoval, T., Rosen, N., Rifkind, R., Marks, P.A. Richon, V.M. (2001) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Research, 61, 8492 8497.
29. Munster, P., Marchion, D., Bicaku, E., Schmitt, M., Lee, J.H., DeConti, R., Simon, G., Fishman, M., Minton, S., Garrett, C., Chiappori, A., Lush, R., Sullivan, D. Daud, A. (2007) Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. Journal of Clinical Oncology, 25, 1979 1985.
30. Murphy, L.D., Valverius, E.M., Tsokos, M., Mickley, L.A., Rosen, N. Bates, S.E. (1990) Modulation of EGF receptor expression by differentiating agents in human colon carcinoma cell lines. Cancer Communications, 2, 345 355.
31. Nguyen, D.M., Schrump, W.D., Chen, G.A., Tsai, W., Nguyen, P., Trepel, J.B. Schrump, D.S. (2004) Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clinical Cancer Research, 10, 1813 1825.
32. Pauer, L.R., Olivares, J., Cunningham, C., Williams, A., Grove, W., Kraker, A., Olson, S. Nemunatis, J. (2004) Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Investigation, 22, 886 896.
33. Picard, S., Titier, K., Etienne, G., Teilhet, E., Ducint, D., Bernard, M.A., Lassalle, R., Marit, G., Reiffers, J., Begaud, B., Moore, N., Molimard, M. Mahon, F.X. (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood, 109, 3496 3499.
34. Piekarz, R.L., Robey, R.W., Zhan, Z., Kayastha, G., Sayah, A., Abdeldaim, A.H., Torrico, S. Bates, S.E. (2004) T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood, 103, 4636 4643.
35. Piekarz, R.L., Gardner, E.R., Zhan, Z., Luchenko, V., Steinberg, S., Liewehr, D., Steadman, K., Frye, R., Figg, W., Prince, M., Allen, S., Zain, J., Kirschbaum, M. Bates, S. (2008) Pharmacokinetic and biomarker analysis in a phase II trial of the HDAC inhibitor romidepsin, FK228. Proceedings of the American Association for Cancer Research, Abstract #5831.
36. Piekarz, R.L., Frye, R., Turner, M., Wright, J.J., Allen, S.L., Kirschbaum, M.H., Zain, J., Prince, H.M., Leonard, J., Geskin, L., Reeder, C., Joske, D., Figg, W.D., Gardner, E.R., Steinberg, S.M., Jafffe, E.S., Stetler-Stevenson, M., Lade, S., Fojo, A.T. Bates, S.E. (2009) A multi-institutional phase II trial of the HDAC inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. Journal of Clinical Oncology, doi :.
37. Richon, V.M., Sandhoff, T.W., Rifkind, R.A. Marks, P.A. (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proceedings of the National Academy of Sciences of the United States of America, 97, 10014 10019.
38. Robey, R.W., Zhan, Z., Piekarz, R.L., Kayastha, G.L., Fojo, T. Bates, S.E. (2006) Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clinical Cancer Research, 12, 1547 1555.
39. Rosato, R.R., Maggio, S.C., Almenara, J.A., Payne, S.G., Atadja, P., Spiegel, S., Dent, P. Grant, S. (2006) The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Molecular Pharmacology, 69, 216 225.
40. Sandor, V., Senderowicz, A., Mertins, S., Sackett, D., Sausville, E., Blagosklonny, M.V. Bates, S.E. (2000a) P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. British Journal of Cancer, 83, 817 825.
41. Sandor, V., Robbins, A.R., Robey, R., Myers, T., Sausville, E., Bates, S.E. Sackett, D.L. (2000b) FR901228 causes mitotic arrest but does not alter microtubule polymerization. Anti-Cancer Drugs, 11, 445 454.
42. Sandor, V., Bakke, S., Robey, R.W., Kang, M.H., Blagosklonny, M.V., Bender, J., Brooks, R., Piekarz, R.L., Tucker, E., Figg, W.D., Chan, K.K., Goldspiel, B., Fojo, A.T., Balcerzak, S.P. Bates, S.E. (2002) Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clinical Cancer Research, 8, 718 728.
43. Shao, R.H., Tian, X., Gorgun, G., Urbano, A.G. Foss, F.M. (2002) Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rbeta gene. Leukemia Research, 26, 1077 1083.
44. Skarpidi, E., Cao, H., Heltweg, B., White, B.F., Marhenke, R.L., Jung, M. Stamatoyannopoulos, G. (2003) Hydroxamide derivatives of short-chain fatty acids are potent inducers of human fetal globin gene expression. Experimental Hematology, 31, 197 203.
45. Steele, N., Vidal, L., Plumb, J., Attard, G., Rasmussen, A., Buhl-Jensen, P., Brown, R., Blagden, S., Evans, J. de Bono, J. (2005) A phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101 in patients with advanced solid tumours. Journal Of Clinical Oncology, 23, 200S.
46. Steele, N.L., Plumb, J.A., Vidal, L., Tjornelund, J., Knoblauch, P., Rasmussen, A., Ooi, C.E., Buhl-Jensenn, P., Brown, R., Evans, T.R. DeBono, J.S. (2008) A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clinical Cancer Research, 14, 804 810.
47. Sutheesophon, K., Nishimura, N., Kobayashi, Y., Furukawa, Y., Kawano, M., Itoh, K., Kano, Y., Ishii, H. Furukawa, Y. (2005) Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228). Journal of Cellular Physiology, 203, 387 397.
48. Svechnikova, I., Almqvist, P.M. Ekström, T.J. (2008) HDAC inhibitors effectively induce cell type-specific differentiation in human glioblastoma cell lines of different origin. International Journal of Oncology, 32, 821 827.
49. Weiser, T.S., Guo, Z.S., Ohnmacht, G.A., Parkhurst, M.L., Tong-On, P., Marincola, F.M., Fischette, M.R., Yu, X., Chen, G.A., Hong, J.A., Stewart, J.H., Nguyen, D.M., Rosenberg, S.A. Schrump, D.S. (2001a) Sequential 5-Aza-2′-deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. Journal of Immunotherapy, 24, 151 161.
50. Weiser, T.S., Ohnmacht, G.A., Guo, Z.S., Fischette, M.R., Chen, G.A., Hong, J.A., Nguyen, D.M. Schrump, D.S. (2001b) Induction of MAGE-3 expression in lung and esophageal cancer cells. Annals of Thoracic Surgery, 71, 295 301.
51. Xiao, J.J., Huang, Y., Dai, Z., Sadee, W., Chen, J., Liu, S., Marcucci, G., Byrd, J., Covey, J.M., Wright, J., Grever, M. Chan, K.K. (2005) Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-Ethylidene]-4, 21-diisopropyl-2-oxa-12,13-dithi a-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16- ene-3,6,9,22-pentanone] Is mediated by reversible MDR1 induction in human cancer cell lines. Journal of Pharmacology and Experimental Therapeutics, 314, 467 475.
52. Yamada, H., Arakawa, Y., Saito, S., Agawa, M., Kano, Y. Horiguchi-Yamada, J. (2006) Depsipeptide-resistant KU812 cells show reversible P-glycoprotein expression, hyper-acetylated histones, and modulated gene expression profile. Leukemia Research, 30, 723 734.